Abstract
TNG961 selectively impairs the viability of FOCAD-negative cells in vitro and inhibits the growth of FOCAD-negative tumors in vivo. A, Relative viability of FOCAD isogenic NCIH1755 cells after 7 days of treatment with the indicated concentrations of TNG961, measured by CellTiter-Glo. Data are mean ± SD (N = 3 biological replicates). B, Relative viability of FOCAD isogenic cell line pairs from the indicated parental models after 7 days of treatment with TNG961, measured by CellTiter-Glo. HAP1 and HeLa are endogenously FOCAD-positive, and isogenic pairs were generated by FOCAD knockout; NCIH1755, MIAPACA2, and MDA-MB-231 are endogenously FOCAD-negative, and isogenic pairs were generated by re-expression of full-length FOCAD cDNA. Selectivity was calculated as potency in FOCAD-positive cells divided by potency in FOCAD-negative cells. Data are mean ± SD (N = 3 biological replicates). C, Potency of TNG961 across a panel of endogenously FOCAD-negative and FOCAD-positive cell lines after 7 days of treatment (maximum concentration 3 µmol/L), measured by CellTiter-Glo (viability assay) and adjusted to free potency to account for serum protein binding (5%–20% across culture conditions). Cell lines with free potency above the maximum concentration tested are plotted at the top dose. Data are mean ± SD (N = 2 technical replicates per model). D, Plasma exposure of TNG961 after 7 days of twice-daily dosing in MIAPACA2 xenograft–bearing mice and corresponding tumor pharmacodynamics assessed by Western blot 12 hours after the last dose (HBS1L protein levels shown as a fraction of the vehicle control band intensity). E–H, Tumor volume over time in mice bearing xenograft tumors (N = 8 mice/arm) from the indicated models treated orally with the indicated doses of TNG961 twice daily for the indicated duration. Data are mean ± SEM.